Sapience Therapeutics

    OverviewSuggest Edit

    Sapience Therapeutics is a company that discovers and develops peptide-based therapeutics. Its drug candidates target protein-protein interactions (PPIs) that are responsible for either making the cells cancerous or dampening the immune response against tumors. The company develops ST-36, a medication designed to treat glioblastoma multiforme (GBM).
    TypePrivate
    Founded2015
    Websitesapiencetherapeutics.com

    Latest Updates

    Employees (est.) (Mar 2020)9

    Key People/Management at Sapience Therapeutics

    Howard Pien

    Howard Pien

    Chairman
    Alice S. Bexon

    Alice S. Bexon

    Chief Medical Officer
    Isaac Blech

    Isaac Blech

    Vice Chairman
    Gene Merutka

    Gene Merutka

    Head of CMC
    Barry Kappel

    Barry Kappel

    President, CEO and Director
    Jim Rotolo

    Jim Rotolo

    Head of Research
    Show more

    Sapience Therapeutics Financials and Metrics

    Summary Metrics

    Founding Date

    2015
    Show all financial metrics

    Sapience Therapeutics Online and Social Media Presence

    Embed Graph

    Sapience Therapeutics Frequently Asked Questions

    • When was Sapience Therapeutics founded?

      Sapience Therapeutics was founded in 2015.

    • Who are Sapience Therapeutics key executives?

      Sapience Therapeutics's key executives are Howard Pien, Alice S. Bexon and Isaac Blech.

    • How many employees does Sapience Therapeutics have?

      Sapience Therapeutics has 9 employees.

    • Who are Sapience Therapeutics competitors?

      Competitors of Sapience Therapeutics include Inovio Pharmaceuticals, Reata Pharmaceuticals and Otonomy.